Abstract: The invention provides for the use of a botulinum toxin to treat contracture, such as muscle contracture, in patients by transdermal administration of the botulinum toxin.
Abstract: The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.
Abstract: The instant invention provides a base material characterized by having a continuous three-dimensional honeycomb structure for regenerating an air sinus. The invention further provides methods for regenerating an air sinus using the base material. The base material has a composition and a structure that is similar to the wall and bone structure which allows it to becomes a scaffold of the regeneration of the mucosa tissue covering the surface of an air sinus.
Abstract: There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azoles such as fluconazole, voriconazole, itraconazole, ketoconazole, miconazole, ER 30346 and SCH 56592; polyenes such as amphotericin B, nystatin, liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or nikkomycin X; other chitin inhibitors; elongation factor inhibitors such as sordarin and analogs thereof; mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127; or complex carbohydrate antifungal agents such as CAN-296; with a lipopeptide compound [I] as described herein.
Abstract: The invention provides a composition and a method for preventing or ameliorating the causes of chronic allograft rejection of a donor organ by a transplant recipient. The method includes concomitant administration to the allograft recipient of therapeutically effective amounts of cyclosporin and 2-chlorodeoxyadenosine. The composition comprises a combination of these two immunosuppressive drugs in therapeutically effective amounts suitable for the practice of the method.
Abstract: Novel bioactive peptide compositions and process for producing the same and the use of such compositions for enhancing the growth of warm blooded animals and fish is disclosed.
Abstract: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.
Type:
Grant
Filed:
June 21, 2004
Date of Patent:
April 15, 2008
Assignees:
Bristol-Myers Squibb Company, President & Fellows of Harvard College
Inventors:
Jeffrey A. Robl, Rex A. Parker, Scott A. Biller, Haris Jamil, Bruce L. Jacobson, Krishna Kodukula, Gokhan Hotamisligil
Abstract: This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition.
Type:
Grant
Filed:
March 5, 2003
Date of Patent:
April 1, 2008
Assignee:
Altus Pharmaceuticals Inc.
Inventors:
Alexey L Margolin, Nazar K Khalaf, Nancy L St Clair, Scott L Rakestraw, Bhami C Shenoy
Abstract: Disclosed is a novel antimicrobial peptide having excellent antimicrobial activities, its analogs and an antimicrobial composition comprising them. The antimicrobial peptide alternatively comprises basic amino acid residues and hydrophobic amino acid residues, and is able to penetrate into microbial cells and act against a wide variety of microorganisms.
Type:
Grant
Filed:
March 26, 2003
Date of Patent:
March 25, 2008
Assignee:
Korea Advanced Institute of Science and Technology
Inventors:
Sun-Chang Kim, In-Yup Park, Ju-Hyun Cho
Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers.
Type:
Grant
Filed:
December 2, 2005
Date of Patent:
February 19, 2008
Assignee:
Incept LLC
Inventors:
Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Peter G. Edelman
Abstract: The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.
Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
Type:
Grant
Filed:
January 20, 2004
Date of Patent:
January 22, 2008
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Cary J. Reich, A. Edward Osawa, Helen Tran
Abstract: The present invention provides peptides having potent anti-angiogenic activity and endothelial cell proliferation inhibition activity. The peptides can be administered as pharmaceutical compositions for prevention or treatment of undesired angiogenesis, for instance for prevention of tumor metastasis or inhibition of primary tumor growth.
Abstract: The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.
Type:
Grant
Filed:
December 11, 2002
Date of Patent:
December 11, 2007
Assignee:
Daiichi Sankyo Co., Ltd.
Inventors:
Hirohiko Arisawa, Hiroaki Masunaga, Hiromi Ogawa, Kanji Higashio
Abstract: Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder.
Abstract: The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent.
Type:
Grant
Filed:
September 25, 2003
Date of Patent:
September 25, 2007
Assignee:
Novo Nordisk A/S
Inventors:
Dorte Lunoe Dunweber, Inge Holm Jensen, Louis Brammer Hansen
Abstract: Method of increasing blood platelet formation by administering a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
Abstract: A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic ?-cell sensitivity to blood glucose levels in a human with IGT. Also, a method for improving the pattern of insulin secretory responses in a human with IGT by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
Type:
Grant
Filed:
May 7, 1999
Date of Patent:
September 4, 2007
Assignee:
Amylin Pharmaceuticals, Inc.
Inventors:
Burkhard Göke, Maria Byrne, Thomas R. Coolidge